Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is a biopharmaceutical company developing neuro-active peptide and related therapeutics for stress-related and central nervous system (CNS) disorders. The PTIX news feed on Stock Titan highlights company announcements that explain how its clinical programs, business transactions, and listing status are evolving over time.
Investors following PTIX news can read detailed updates on the company’s lead peptide candidate, PT00114, including milestones in single ascending dose and multiple-dose Phase 1 studies in healthy volunteers. Recent press releases describe safety, tolerability, and pharmacokinetic findings for PT00114, as well as the company’s plans to use Phase 1 data to support advancement into Phase 2 studies in stress-related and mood disorders such as depression, anxiety, and PTSD.
News coverage also includes pipeline and corporate developments, such as the announced business combination with Phytanix Bio Inc. to form a combined entity called Phytanix, Inc. Company statements outline how this transaction adds preclinical CNS assets, including a potassium channel modulator, cannabinoid-based compounds with composition-of-matter IP, and modified stilbenoid candidates with anticonvulsant activity in preclinical models.
In addition, PTIX news items feature capital markets and regulatory updates, including private placements, warrant exercises, a 1-for-14 reverse stock split intended to address Nasdaq minimum bid price requirements, and Nasdaq notices related to continued listing standards and periodic filing timelines. Legal filings connected to the Phytanix share exchange agreement and other governance matters are also reported through current reports and press releases. By reviewing this news stream, readers can see how Protagenic describes the progress of its CNS-focused pipeline, its financing activities, and its efforts to manage exchange listing and regulatory obligations.
Summary not available.
Summary not available.
Summary not available.
Protagenic Therapeutics (Nasdaq:PTIX) announced a 1-for-4 reverse stock split effective March 23, 2023, to comply with Nasdaq's minimum bid price requirement. This decision follows shareholder approval on November 23, 2022. The reverse split will convert every four shares into one, reducing the outstanding shares from approximately 17.3 million to about 4.3 million. All stockholders will be uniformly affected, and no fractional shares will be issued. The aim is to increase the stock price above $1.00 for continued listing. Comprehensive details are available on the company’s website and SEC filings.
Protagenic Therapeutics (NASDAQ:PTIX) announced its participation in the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference set for April 27, 2022, at 10:30 AM ET. The biopharmaceutical company, focused on treating stress-related neurologic disorders, will present on its pre-clinical drug candidates. Investors interested in the conference can access the presentation via this link. For further inquiries or to schedule one-on-one meetings, attendees are encouraged to contact their conference representative.
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) reported its Q3 2021 results, highlighting significant advancements in developing PT00114 for stress-related neurological disorders. The company hosted a virtual science review and KOL webinar, discussing PT00114's potential for treating depression, anxiety, PTSD, and addiction. Financially, net loss decreased to approximately $0.9 million from $1.0 million year-over-year, with R&D expenses also down at $0.3 million. The company holds $10.8 million in cash and plans to refile its IND application in Q4 2021, with a Phase I/IIa study set for Q1 2022.
Protagenic Therapeutics (Nasdaq: PTIX) announces a scientific webinar on September 8, 2021, focused on its neuro-active peptide PT00114, intended for treating Depression, Anxiety, PTSD, and Addiction. The session will feature presentations by key figures including David Lovejoy and Andrew Slee, discussing PT00114's discovery, evidence from disease models, and its role in addiction therapy. The event, lasting from 10:00 AM to 11:00 AM ET, will conclude with a Q&A. Registration is available on Protagenic's website.
Protagenic Therapeutics (PTIX) reported a net loss of approximately $1.5 million for Q2 2021, up from $0.6 million in Q2 2020. Operating and administrative expenses rose significantly, with general and administrative costs reaching about $1.2 million, compared to $0.4 million the prior year. The company closed a $13.2 million public offering and plans to refile its IND application for PT00114 in Q4 2021, with a Phase I/IIa study set to initiate in Q1 2022. As of June 30, 2021, PTIX had $11.9 million in cash and approximately 16.6 million shares outstanding.
Protagenic Therapeutics (Nasdaq: PTIX) announced that the FDA has requested the company to provide clinical sites with ready-to-inject vials instead of drug substances for local formulation. This change allows Protagenic to maintain control over the final drug product formulation. The company plans to comply with this directive and refile its Investigational New Drug (IND) application to initiate patient enrollment in Q4 2021. The company focuses on developing therapies for stress-related neurologic disorders.
Protagenic Therapeutics (Nasdaq: PTIX) will host a webinar on July 13, 2021, at 10:00 AM ET, to discuss PT00114, a potential treatment for stress-related disorders such as Depression, PTSD, Anxiety, and Addiction. The webinar features Dr. Maurizio Fava, a leading psychiatrist and principal investigator for the upcoming Phase 1/2a trial. He will provide insights into the clinical development of PT00114, a peptide aimed at regulating stress response in the brain. Interested participants can contact James Carbonara at Hayden IR for registration details.